

INNOVATION SCIENCE AND TECHNOLOGY



Scopus || Electronic journal specializing in Scopus

ISSUE 7



Acceptance of papers **July, 2025**



Acceptance of papers

Published monthly



Topics

economics, technology, social sciences

ISSN 3060-5229



Digital Object Identifier



Visit the website t.me/scopus_IST2100



EDITOR-IN-CHIEF:

Mirzaliev Sanjar Makhmatjon ugli

DEPUTY EDITOR-IN-CHIEF:

Makhmudov Nosir Makhmudovich
DSc., Prof., Academician

DEPUTY EDITOR-IN-CHIEF:

Ochilov Bobur Bakhtiyor ugli – Senior
lecturer at TSUI

THE SCIENTIFIC-POPULAR ELECTRONIC
JOURNAL **"INNOVATION SCIENCE AND
TECHNOLOGY"** HAS BEEN REGISTERED
UNDER THE NUMBER **C-5669633** BY THE
AGENCY FOR INFORMATION AND MASS
COMMUNICATIONS (AOKA) OF THE
REPUBLIC OF UZBEKISTAN, EFFECTIVE
FROM OCTOBER 9, 2024.

CONTACTS

Phone: **97-748-70-03**

Website: <https://ist-journal.uz>

Email: munis.iriskulova@gmail.com

The scientific electronic journal "Innovation Science and Technology" has been included in the list of scientific publications recommended for the publication of main scientific results of dissertations for the award of PhD and DSc degrees in economics and technical sciences, in accordance with the Resolution No. 370 of the Presidium of the Higher Attestation Commission of the Republic of Uzbekistan, dated May 8, 2025.

Editorial board:



Sharipov Kongiratbay Avezimbetovich,
Doctor of Technical Sciences (DSc), Professor



Abdurakhmanova Gulnora Kalandarovna,
Doctor of Economic Sciences (DSc), Professor



Cham Tat Huei,
Doctor of Philosophy (PhD), Professor (Malaysia)



Muhammad Imran Sadiq
Doctor of Philosophy in Economics (PhD),
Professor, Malaysia



Ahmed Aziz Ismail
Doctor of Technical Sciences (DSc),
Professor (Egypt)



Lee Chin
Doctor of Philosophy in Economics (PhD),
(Malaysia)



Asongu Simplicé
Doctor of Philosophy in Economics (PhD),
Cameroon



Rui Dang
Doctor of Chemistry (DSc), Professor, China



Zahoor Ahmed
Doctor of Philosophy in Economics (PhD), Turkey



Shujaat Abbas
Doctor of Philosophy in Economics (PhD), Russia



Tina A Coffelt
Doctor of Philosophy in Educational Sciences
(PhD), USA



Judy B. Smetana
Doctor of Philosophy in Economics (PhD), USA

CONTENTS

Nephrogenic anemia as a risk factor for the development of cardiovascular disorders
in children with chronic kidney disease 6
Aralov Mirza Dzhurakulovich

CONTENTS



NEPHROGENIC ANEMIA AS A RISK FACTOR FOR THE DEVELOPMENT OF CARDIOVASCULAR DISORDERS IN CHILDREN WITH CHRONIC KIDNEY DISEASE

Aralov Mirza Dzhurakulovich

ORCID: 0009-0008-5767-5179

Samarkand State Medical University

Uzbekistan, Samarkand, 18 Amir Temur Street

Email: sammu@sammu.uz

Abstract: A total of 260 children with chronic kidney disease (CKD) were examined. Anemia was present in 217 patients, accounting for 83.5%, and among children with cardiovascular disorders, it was observed in 90.2% of cases (110 out of 122 patients). The interrelation between cardiovascular disorders, CKD, and anemia lies in the fact that anemia affects the course of CKD and the development of cardiovascular pathology. Anemia in children with CKD plays a key role in the pathogenesis of cardiovascular damage through hypoxic injury to the myocardium. Restoration of hemoglobin levels is essential even at the early stages of CKD, as it is crucial for preventing cardiovascular complications, which are the leading cause of death among children and adolescents with CKD.

Key words: Nephrogenic Anemia, Chronic Kidney Disease (CKD), Cardiovascular Disorders, Children, Risk Factor, Erythropoietin (EPO), Iron Deficiency, Hypertension, Left Ventricular Hypertrophy, Cardiovascular Morbidity.

INTRODUCTION

Recent studies on the course of chronic kidney disease (CKD) have revealed a close relationship between the progression of renal pathology and the condition of the cardiovascular system [2, 3, 5, 6, 11]. The development of cardiovascular disorders (CVD) is associated with the emergence of risk factors arising from the progression of CKD, one of which is anemia [3, 7, 11]. The chronic inflammatory process in kidney tissue leads to renal shrinkage and a decrease in the number of peritubular cells in the proximal nephron, thereby impairing the production of erythropoietin — a key component of hematopoiesis [10]. Nephrogenic anemia predictably complicates the course of CKD and is more commonly diagnosed when the glomerular filtration rate (GFR) declines to 40–60 ml/min/1.73 m², although it can be detected at earlier stages of the disease [1, 12]. Anemia is associated with complications such as increased rates of hospitalization and mortality, as well as the progression of cardiovascular risk factors, including left ventricular hypertrophy (LVH) [4, 9, 12]. The increased oxygen demand of the myocardium contributes to subendocardial ischemia, increased ventricular stiffness, reduced aortic compliance, and greater arterial stiffness — all of which underlie the development of diastolic heart failure [3, 5].

LITERATURE REVIEW ON THE TOPIC

To determine the significance of nephrogenic anemia as a factor in the development of cardiovascular disorders in children with chronic kidney disease.

After the task force publication, Parekh et al.⁴ used the USRDS database to evaluate the risk of cardiac death in children and young adults (aged 0–30 years) in 2002. Of 1380 deaths recorded between 1990 and 1996, 311 (23%) were due to cardiac causes. These data are in sharp contrast to the general pediatric population, in which CVD mortality is very low and accounts for <3% of all deaths.

Subsequent reports from international registries confirm that CVD is the leading cause of death in both children with ESRD and in adults with childhood onset of CKD. The Australia and New Zealand Dialysis and Transplant,⁵ Dutch national cohort study,⁶ and a large German study⁷ reported that 40%–50% of all deaths are from cardiovascular or cerebrovascular causes.

RESEARCH METHODOLOGY

We examined 260 children with CKD in pre-dialysis stages (stages I–IV), aged 5 to 17 years. The underlying causes of CKD were chronic glomerular pathology in 56.8% of cases and congenital anomalies of the urinary system in 43.2%. Based on clinical, laboratory, and instrumental assessments, the children were divided into two groups. The first group included 122 children with diagnosed cardiovascular abnormalities — such as conduction system blocks on ECG, left ventricular myocardial hypertrophy, repolarization disorders, metabolic changes in the myocardium, and signs of cardiac remodeling on echocardiography (EchoCG). The second group included 138 patients without such changes.

ANALYSIS AND RESULTS

We analyzed the clinical course of CKD in children depending on the presence of cardiovascular disorders. Our findings revealed that CVD in children most frequently develops during stages 3 and 4 of CKD. The data are presented in Table 1.

Table 1. Distribution of Examined Children With and Without Cardiovascular Disorders Depending on the Stage of Chronic Kidney Disease (CKD)

Number of patients 1 st. CKD		Stages of CKD			
		2 st. CKD	3 st. CKD		4 st. CKD
1 group, n=122	abs.	6	18	55	43
	%	4,9	14,7	45,1	35,3
2 group, n=138	abs.	15	49	50	24
	%	10,9*	35,5*	36,2	17,4*
Total, n=260	abs.	21	67	105	67
	%	8,1	25,8	40,4	25,8

Note: * — statistically significant difference between groups ($p < 0.05$).

As shown in the table, in the group of children with cardiovascular disorders (CVD), stage 1 CKD was recorded 2.2 times less frequently compared to the second group (4.9% vs. 10.9%; $p = 0.003$); stage 2 CKD — 2.4 times less frequently (14.7% vs. 35.5%; $p = 0.004$); stage 3 — 1.2 times more frequently (45.1% vs. 36.2%; $p = 0.006$); and stage 4 CKD — 2 times more frequently than in the group of children without CVD (35.3% vs. 17.4%; $p = 0.003$).

Among the factors influencing the development of CVD in children with CKD, we found that congenital anomalies of the urinary system (CAKUT) were less frequently associated with CVD, whereas chronic glomerular diseases were significantly more likely to be predictors of cardiovascular disorders in children. The data are presented in Table 2.

Table 2. Distribution of Examined Children With and Without Cardiovascular Disorders Depending on the Cause of CKD

Causes	1 group, n=122		2 group, n=138	
	abs.	%	abs.	%
Glomerular diseases, n=144	74	60,7	70	50,7
Congenital malformations (CA), n=116	48	39,3	68	49,3

When analyzing the development of cardiovascular disorders in relation to glomerular filtration rate (GFR) (Table 3), we found that children in Group 1 had significantly lower GFR values compared to those in Group 2 — averaging 44.1 ± 2.1 ml/min/1.73 m² versus 56.2 ± 2.1 ml/min/1.73 m², respectively ($p < 0.01$). A consistent pattern was observed: the frequency of cardiovascular disorders increased as GFR declined. For instance, when GFR ranged between 90–120 ml/min/1.73 m², the incidence of CVD was 4.9%, whereas at GFR levels of 15–29 ml/min/1.73 m², the incidence increased by 7.4 times ($p < 0.01$).

Table 3. Frequency of Cardiovascular Pathology Depending on GFR Levels

Degree of kidney impairment by GFR, mL/min/1.73m ²	1 group, n=122		2 group, n=138	
	abs.	%	abs.	%
90-120	6	4,9	13	9,4*
60-89	18	14,7	50	36,2**
30-59	54	44,3	51	37,0
15-29	44	36,1	24	17,4*
Total	44,1±2,1		56,2±2,1*	

Note: * — statistically significant difference between groups ($p < 0.05$).

A comparative analysis of hematological parameters (Table 4) showed that in children with cardiovascular disorders (CVD) associated with CKD, mean hemoglobin levels were significantly reduced — by 1.4 times compared to the control group ($p < 0.01$) and by 1.1 times compared to children with CKD without CVD ($p < 0.05$).

Table 4. Complete Blood Count Results in Children With CKD Depending on the Presence of Cardiovascular Pathology

	Parameters	1 group, n=122	2 group, n=138	Control group
1	Hb, g/L	82,6±1,9**	94,3±1,5*^	115,2±4,4
2	Red blood cells (RBCs), x 10 ¹² /L	3,1±0,05*	3,7±0,1*	4,4±0,9
3	Color index (CI)	0,71±0,08**	0,85±0,07*^	0,9±0,06

Note: * - statistically significant compared to control group (* - $p < 0.05$; ** - $p < 0.01$); * - statistically significant difference between Group 1 and Group 2 (^ - $p < 0.05$).

Red blood cell (RBC) count in children with CKD was significantly reduced compared to the control group — by 1.4 times ($p < 0.05$), and by 1.2 times compared to patients in Group 2 ($p < 0.05$). A decrease in the color index (CI) was also noted in children with CKD. In the presence of cardiovascular disorders, the CI was reduced by 1.3 times compared to the control group ($p < 0.05$) and by 1.2 times compared to Group 2 ($p < 0.05$).

An odds ratio analysis was performed to identify the most significant hematological predictors for the development of cardiovascular disorders in children with CKD — specifically, a reduction in hemoglobin, red blood cells, and color index (Table 4).

Table 5. Results of Factor Analysis of Hematological Predictors for the Development of Cardiovascular Pathology in Children With CKD

Hematological parameters	1 group, n=122		2 group, n=138	
	abs.	%	abs.	%
Decreased hemoglobin	110	90,2	107	77,5
Decreased red blood cells (RBCs)	112	91,8	105	76,1
Decreased color index (CI)	108	88,5	98	71,0

In our study, anemia was found in 217 children with CKD, accounting for 83.5% of cases. Among children with cardiovascular disorders (CVD), the incidence of anemia was 90.2% (110 out of 122 patients). The link between cardiovascular disorders, CKD, and anemia lies in the fact that anemia influences the progression of CKD and the development of cardiovascular pathology. Notably, the severity of anemia tends to be more pronounced in patients with advanced stages of chronic kidney disease.

CONCLUSION AND SUGGESTIONS

Thus, reductions in hemoglobin levels, red blood cell count, and color index are among the most informative indicators for assessing the degree of circulatory impairment. These parameters not only reflect the severity of hemodynamic disturbances in patients with CKD but also play a role in the pathogenesis of cardiovascular damage through hypoxic injury to the myocardium. Restoration of hemoglobin levels is necessary even at the early stages of CKD, as even slight improvements in cardiovascular function following full correction of anemia play a crucial role in preventing cardiovascular complications — the leading cause of death among children and adolescents with CKD.

REFERENCES

1. Aitbaev K.A., Murkamilov I.T., Fomin V.V. Nephrogenic anemia: new physiological approaches to therapy based on hypoxia-mimicking strategies. *Almanac of Clinical Medicine*. 2017 Nov; 45(7): 565–574. doi: 10.18786/2072-0505-2017-45-7-565-574
2. Aksenova M.E. Mechanisms of cardiovascular pathology in chronic kidney disease. *Practical Medicine*. 2018. Vol. 16, No. 8, pp. 21–26.
3. Savenkova N.D., Grigoryeva O.P. Prognosis of cardiovascular complications and renal failure in pediatric CKD patients based on NKF-K/DOQI (2002) and KDIGO (2012) classifications. *Russian Bulletin of Perinatology and Pediatrics*. 2022; 67(2): 12–19.
4. Sedov D.S. Cardiac remodeling in patients with chronic kidney disease (review). *Saratov Journal of Medical Scientific Research*. 2019. Vol. 15, No. 2, pp. 217–221.
5. Yuldashev B.A., Shamsiev A.M. Echocardiography in the diagnosis of cardiovascular disorders in children with CKD. *New Day in Medicine – 2024*. No. 10 (72), pp. 159–163.
6. Yuldashev B.A. Pathomorphological features of myocardial remodeling depending on the progression of CKD in children. *Problems of Biology and Medicine – 2024*. No. 5, pp. 270–272.
7. Atkinson M.A., White C.T. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. *Pediatr Nephrol*. 2012 Jan; 27(1): 33–40. doi: 10.1007/s00467-011-1832-y. Epub 2011 Mar 13. PMID: 2140018
8. Chesnaye N.C., Schaefer F., Groothoff J.W., et al. Mortality risk in European children with end-stage renal disease on dialysis. *Kidney International*. 2016; 89: 1355–1362.
9. Gerson A., Hwang W., Fiorenza J., et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. *Am J Kidney Dis*. 2004 Dec; 44(6): 1017–1023. doi: 10.1053/j.ajkd.2004.08.024. PMID: 15558522
10. Jelkmann W. Regulation of erythropoietin production. *J Physiol*. 2011 Mar 15; 589 (Pt 6): 1251–1258. doi: 10.1113/jphysiol.2010.195057. Epub 2010 Nov 15. PMID: 21078592; PMCID: PMC3082088
11. Mitsnefes M.M. Cardiovascular disease in children with chronic kidney disease. *J Am Soc Nephrol*. 2012; 23: 578–585.
12. Perlman R.L., Finkelstein F.O., Liu L., et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. *Am J Kidney Dis*. 2005; 45(4): 658–666. [PubMed: 15806468]

Proofreader: Zokir ALIBEKOV

Layout and Designer: Oloviddin Sobir ugli

2025. № 7

© When materials are reproduced, the INNOVATION SCIENCE AND TECHNOLOGY journal must be cited as the source. Authors are responsible for the accuracy of the information in materials and advertisements published in the journal. Editorial opinions may not always align with those of the authors. Submitted materials will not be returned to the editorial office.

To publish articles in this journal, you may submit articles, advertisements, stories, and other creative materials through the following links. Materials and advertisements are published on a paid basis.

You may subscribe to the journal at any time using the following details. Once subscribed, please send a screenshot or photo of your payment confirmation to our Telegram page @iqtisodiyot_77. Based on this, we will send the latest issue of the journal to your address each month.

“The journal “INNOVATION SCIENCE AND TECHNOLOGY” has been registered by the Agency for Information and Mass Communications under the Administration of the President of the Republic of Uzbekistan from 09.10.2024 under the registration number №390637. License number: C-5669633. PNFL: 30407832680027

Our address: Tashkent city, Yunusobod district, 19th block,
House 17.



Acceptance of articles

Published every
monthly



Directions

Social, economic, political,
technological, scientific



Scopus || Scientific electronic journal specializing in Scopus

CERTIFICATE NUMBER: №390637

**ORDER NUMBER ACCORDING TO
THE LICENSE REGISTER: C-5669633**

CONTACT:



Contact us
+998 97 748 70 03



Telegram channel
t.me/scopus_IST2100



Journal official website
<https://ist-journal.uz/index.php/IST>